Do you want to read an article? Please log in or register.
NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer
Breast Cancer
ASCO 2024
Related content
ASCO 2024
Breast Cancer
monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer
SABCS 2024
Breast Cancer
PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer
SABCS 2024
Breast Cancer
OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer
Breast Cancer
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
Ann Oncol
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D
doi: 10.1016/j.annonc.2024.10.015
SABCS 2024
Breast Cancer
Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291
RECOMMENDED
Breast Cancer
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Eur J Cancer
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G
doi: 10.1016/j.ejca.2024.113535
Breast Cancer
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial
Eur J Cancer
Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, Bengala C, Risi E, Molinara E, Pazzagli I, Malorni L, Donati S, Gabellini S, Martignetti A, Giannessi P, Sanna G, Barellini L, Biagioni C, Boni L, Bianchi S, Roncella M, Biganzoli L
doi: 10.1016/j.ejca.2024.115108
Breast Cancer
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Clin Cancer Res
Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L
doi: 10.1158/1078-0432.CCR-24-1553
SABCS 2024
Breast Cancer